Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913884 | 0.89 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL28569492 | 0.87 | NR1H2 (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31420745 | 0.87 | NR1H2 (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2348311 | 0.87 | NR1H2 (0.49) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16008355 | 0.87 | NR1H2 (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20913888 | 0.87 | GPR119 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31511673 | 0.85 | GPR119 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20913835 | 0.84 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19448428 | 0.84 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL29831252 | 0.84 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-111918651-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2683716-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | Glaxo Group Limited (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-01-02 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536283-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011103091-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | NR1H2 2597/4885MEN1 3382/4885ALDH1A1 2833/4885 |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | AGER, PSEN2, PSEN1 | NR1H2 249/4885MEN1 2797/4885ALDH1A1 461/4885 |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, PSEN2, PSEN1 | NR1H2 249/4885MEN1 2797/4885ALDH1A1 461/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | NR1H2 1503/4885MEN1 3168/4885ALDH1A1 4414/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | NR1H2 2983/4885MEN1 3537/4885ALDH1A1 4754/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | NR1H2 1503/4885MEN1 3168/4885ALDH1A1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.